D.A. Davidson & CO. purchased a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 40,660 shares of the medical equipment provider's stock, valued at approximately $1,018,000. D.A. Davidson & CO. owned approximately 0.09% of BioLife Solutions as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently made changes to their positions in the stock. 1620 Investment Advisors Inc. acquired a new position in BioLife Solutions during the 2nd quarter worth approximately $35,000. Isthmus Partners LLC grew its position in BioLife Solutions by 34.4% in the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 42,265 shares in the last quarter. Quest Partners LLC bought a new stake in BioLife Solutions during the 3rd quarter worth about $57,000. GAMMA Investing LLC grew its holdings in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider's stock valued at $83,000 after acquiring an additional 748 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of BioLife Solutions in the second quarter valued at about $122,000. Institutional investors own 93.24% of the company's stock.
BioLife Solutions Price Performance
Shares of NASDAQ BLFS traded down $0.22 during mid-day trading on Monday, hitting $27.25. 241,377 shares of the stock traded hands, compared to its average volume of 388,292. The firm has a 50 day simple moving average of $24.23 and a two-hundred day simple moving average of $23.25. The company has a market cap of $1.26 billion, a PE ratio of -25.92 and a beta of 1.88. BioLife Solutions, Inc. has a twelve month low of $12.45 and a twelve month high of $28.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.
Insider Transactions at BioLife Solutions
In related news, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $23.28, for a total transaction of $232,800.00. Following the transaction, the executive vice president now directly owns 317,716 shares of the company's stock, valued at $7,396,428.48. This represents a 3.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CRO Garrie Richardson sold 3,070 shares of the firm's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now owns 114,773 shares of the company's stock, valued at approximately $2,883,097.76. This represents a 2.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,313 shares of company stock worth $1,572,899 over the last ninety days. 2.20% of the stock is owned by insiders.
Analyst Ratings Changes
BLFS has been the topic of a number of recent analyst reports. TD Cowen boosted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Craig Hallum raised their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Northland Securities increased their price target on BioLife Solutions from $26.00 to $28.00 and gave the stock an "outperform" rating in a research report on Friday, August 9th. Finally, HC Wainwright cut their target price on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating for the company in a research report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, BioLife Solutions currently has a consensus rating of "Moderate Buy" and a consensus price target of $27.50.
View Our Latest Stock Analysis on BLFS
BioLife Solutions Company Profile
(
Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Featured Articles
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.